BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,754,859 | -14.6% | 1,627,073 | +2.4% | 0.02% | -16.0% |
| Q2 2023 | $129,697,826 | +8.7% | 1,588,850 | -1.2% | 0.02% | +4.2% |
| Q1 2023 | $119,276,821 | -12.9% | 1,607,721 | -2.6% | 0.02% | -17.2% |
| Q4 2022 | $136,873,668 | +20.4% | 1,651,468 | +312.5% | 0.03% | +11.5% |
| Q3 2022 | $113,704,000 | -20.8% | 400,365 | -3.3% | 0.03% | -16.1% |
| Q2 2022 | $143,480,000 | -24.9% | 413,918 | -6.2% | 0.03% | -8.8% |
| Q1 2022 | $191,117,000 | -16.8% | 441,339 | -0.6% | 0.03% | -10.5% |
| Q4 2021 | $229,782,000 | +5.9% | 444,161 | -0.8% | 0.04% | 0.0% |
| Q3 2021 | $217,065,000 | +14.1% | 447,956 | +6.0% | 0.04% | +11.8% |
| Q2 2021 | $190,207,000 | +35.8% | 422,436 | +15.2% | 0.03% | +30.8% |
| Q1 2021 | $140,048,000 | +24.4% | 366,684 | +3.4% | 0.03% | +18.2% |
| Q4 2020 | $112,585,000 | +28.4% | 354,540 | +0.2% | 0.02% | +15.8% |
| Q3 2020 | $87,673,000 | -8.4% | 353,905 | -2.4% | 0.02% | -17.4% |
| Q2 2020 | $95,763,000 | +46.1% | 362,641 | +4.9% | 0.02% | +21.1% |
| Q1 2020 | $65,545,000 | -10.8% | 345,662 | +3.3% | 0.02% | +18.8% |
| Q4 2019 | $73,455,000 | +14.6% | 334,630 | +2.2% | 0.02% | +6.7% |
| Q3 2019 | $64,091,000 | -7.4% | 327,542 | -1.3% | 0.02% | -6.2% |
| Q2 2019 | $69,199,000 | +3.7% | 331,906 | -1.3% | 0.02% | 0.0% |
| Q1 2019 | $66,758,000 | +40.5% | 336,227 | +2.4% | 0.02% | +23.1% |
| Q4 2018 | $47,503,000 | -33.9% | 328,241 | -6.8% | 0.01% | -27.8% |
| Q3 2018 | $71,919,000 | +31.0% | 352,358 | -5.1% | 0.02% | +28.6% |
| Q2 2018 | $54,914,000 | -4.2% | 371,162 | -2.2% | 0.01% | -6.7% |
| Q1 2018 | $57,308,000 | +16.5% | 379,422 | -0.1% | 0.02% | +25.0% |
| Q4 2017 | $49,207,000 | -4.7% | 379,833 | -11.1% | 0.01% | -7.7% |
| Q3 2017 | $51,631,000 | -5.9% | 427,097 | -8.6% | 0.01% | -13.3% |
| Q2 2017 | $54,879,000 | +10.4% | 467,059 | -4.5% | 0.02% | +7.1% |
| Q1 2017 | $49,704,000 | +24.0% | 488,970 | +25.4% | 0.01% | +16.7% |
| Q4 2016 | $40,091,000 | -29.0% | 389,881 | -24.4% | 0.01% | -33.3% |
| Q3 2016 | $56,435,000 | -2.5% | 515,389 | +0.5% | 0.02% | -5.3% |
| Q2 2016 | $57,853,000 | +22.8% | 513,012 | +2.3% | 0.02% | +18.8% |
| Q1 2016 | $47,122,000 | +6.6% | 501,382 | +2.1% | 0.02% | +6.7% |
| Q4 2015 | $44,195,000 | +0.5% | 491,061 | +3.2% | 0.02% | 0.0% |
| Q3 2015 | $43,996,000 | +21.6% | 475,850 | +29.5% | 0.02% | +36.4% |
| Q2 2015 | $36,173,000 | -29.2% | 367,339 | -27.8% | 0.01% | -26.7% |
| Q1 2015 | $51,058,000 | +19.4% | 509,108 | +10.0% | 0.02% | +15.4% |
| Q4 2014 | $42,749,000 | – | 462,638 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |